Nuvectis Pharma股价因1亿美元股票发行定价而下跌19%

2026-06-30 12:09

Nuvectis Pharma (NVCT) had priced its underwritten public offering of 5M shares of its common stock at $20 per share, with expected gross proceeds of $100M, the company said Monday, sending shares down 19% in after-market trading.
Nuvectis has also granted the underwriters a 30-day option to purchase up to 750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.
The offering is expected to close on or about July 1. Nuvectis intends to use net proceeds from the offering to continue to advance the development programs of NXP100, NXP200, and NXP900 or any future product candidate.
It also looks to also use proceeds for hiring additional personnel, capital expenditures, costs of operating as a public company, and other general corporate purposes.

More on Nuvectis Pharma